Methimazole (Tapazole) Cost in South Dakota: 2026 Prices, Insurance, and Savings

Methimazole (brand name Tapazole) is an oral thionamide antithyroid drug, FDA-approved for treating hyperthyroidism, including Graves disease. It is available as a generic tablet and is not the same drug as propylthiouracil (PTU), a related but chemically distinct thionamide reserved mainly for early pregnancy and thyroid storm.

What is actually established: Generic methimazole is an off-patent, widely stocked oral drug, which generally keeps its cash price low relative to brand-only medications. Medicare Part D beneficiaries nationwide, including in South Dakota, are protected by a $2,000 annual out-of-pocket cap on covered drug costs under the Inflation Reduction Act, effective since 2025 (CMS). What is not established from the sources available to build this page: a specific South Dakota retail cash price, a specific South Dakota Medicaid coverage decision for methimazole, specific insurer copay tiers at named South Dakota health plans, and specific 340B or discount-card savings figures. Those numbers move often, were not verifiable against a dated primary source at the time of writing, and should not be treated as current facts. If you need an exact number, confirm it the same week you plan to fill the prescription.

Why this page narrows its own claims

An earlier version of this page stated precise figures such as "$15 per month cash price in South Dakota," "$80 manufacturer list price," and "South Dakota Medicaid does not cover methimazole," along with a quoted sentence attributed to American Thyroid Association guidelines. None of those specific figures or the quotation could be verified against a dated, checkable primary source for this rewrite. Rather than repeat unverified numbers as fact, this version explains what drives methimazole cost in general, flags exactly which South Dakota-specific facts need direct confirmation, and gives you a way to check them yourself.

This distinction matters for a YMYL medication page. A wrong drug price is an inconvenience. A wrong statement about Medicaid coverage or a fabricated guideline quote can change how a patient or caregiver makes a treatment decision.

What drives methimazole's price, generally

Methimazole has been generically available for decades, and generic thionamide antithyroid drugs are typically inexpensive compared to newer or brand-protected drugs. Brand-name Tapazole exists but is rarely dispensed once a generic is on the market, because state pharmacy substitution laws generally require or allow automatic substitution of an AB-rated generic unless a prescriber specifies "dispense as written."

Cash price at any individual pharmacy, in South Dakota or elsewhere, depends on the pharmacy's acquisition cost, its markup, whether a discount card or coupon is applied, and whether the fill goes through insurance or is paid cash. This means the same tablet can have meaningfully different sticker prices across pharmacies in the same town, and a discount coupon can sometimes beat an insurance copay. None of this is South Dakota-specific; it is true of most generic oral drugs nationally. Confirming an exact number requires calling the pharmacy or checking a real-time pricing tool the same day.

Does South Dakota Medicaid cover methimazole?

This is a genuinely important question for low-income patients, and it is also the fact most likely to change without notice. Medicaid preferred drug lists are set and updated by each state's Medicaid program, and coverage status for a specific generic drug can shift with formulary updates, prior authorization rules, or managed care organization contracts. No dated, checkable South Dakota Medicaid document was available to confirm methimazole's current formulary status for this rewrite, so this page does not assert a coverage answer either way.

If you or a family member is on South Dakota Medicaid, the reliable path is to call South Dakota Medicaid member services or ask the dispensing pharmacy to run a test claim, which will show a covered price, a prior-authorization requirement, or a denial in real time. If a prior authorization is required, your prescriber can typically submit one, and case-by-case approval is a realistic outcome for drugs with no good substitute, though approval is never guaranteed.

Insurance coverage: what is generally true, and what needs confirmation

Commercial insurance and Medicare Part D plans in most states place generic methimazole on a low formulary tier, because it is an inexpensive generic with no comparably effective, similarly priced brand alternative for most patients. That general pattern is plausible for South Dakota plans as well, but this page cannot confirm specific tier placement, specific copay amounts, or specific insurer names (for example, whichever regional plans a reader may be enrolled in) without a current, dated formulary document, which was not available as source material here. Check your plan's own formulary document or call member services, since formularies are updated annually and sometimes mid-year.

The Medicare Part D $2,000 annual out-of-pocket cap, in effect since 2025, is a stable federal policy fact that applies regardless of state (CMS). For a low-cost generic like methimazole, most Medicare beneficiaries would not be expected to come close to that cap from this drug alone, though total drug spending across all prescriptions is what counts toward it.

Compounded methimazole

Compounding is a real and legal option, governed by a stable federal framework rather than a South Dakota-specific rule. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed pharmacies may compound a patient-specific preparation, such as a liquid formulation or a non-standard tablet strength, based on a valid prescription. Section 503B outsourcing facilities compound at larger scale under FDA-registered current good manufacturing practice (cGMP) requirements and can supply pharmacies without a patient-specific prescription in some circumstances. Every state, including South Dakota, licenses pharmacies to operate under 503A, but the pharmacy's own licensing status and scope should be confirmed directly with the pharmacy and, if in doubt, with the South Dakota Board of Pharmacy.

Compounding is most clinically relevant when the commercially manufactured 5 mg and 10 mg tablet strengths do not match a prescribed dose, for example during a slow taper. It is not usually cheaper than a standard generic tablet, and its price varies by pharmacy and preparation, so it should not be assumed to be a cost-saving option by default.

Telehealth prescribing

Telehealth prescribing of non-controlled medications like methimazole is broadly permitted across the United States when performed by a licensed provider following applicable state telehealth rules, and this is consistent with what is generally known about state telehealth parity laws. For a patient in a rural part of South Dakota without local access to an endocrinologist, a telehealth visit can support initial evaluation, prescribing, and interpretation of periodic thyroid function tests drawn at a local lab. Confirm your specific provider's licensure in South Dakota and whether your insurance reimburses the telehealth visit type, since telehealth coverage and reimbursement rules also change and are not uniform across every plan.

How methimazole compares to other hyperthyroidism treatments

Methimazole is one of several accepted treatment paths for hyperthyroidism, and cost is only one factor in choosing among them.

Exact dollar ranges for RAI and surgery vary widely by facility and were not independently verified for this page; treat any specific figure you encounter elsewhere as an estimate to confirm with the treating facility.

Monitoring is part of the real cost

The drug itself is only part of the cost of treating hyperthyroidism with methimazole. Guideline-level practice for antithyroid drug therapy generally calls for periodic thyroid function testing (TSH and free T4) during dose titration and less frequent testing once a patient is stable; a complete blood count is standard before starting therapy given the rare risk of agranulocytosis. Confirm the exact interval your prescriber wants with your own care team rather than assuming a fixed schedule, since it depends on how quickly your levels respond.

Patients should stop methimazole and seek prompt medical evaluation, including a white blood cell count with differential, if they develop fever, sore throat, or mouth ulcers while on the drug, since these can be early signs of agranulocytosis. This is a widely recognized safety instruction for thionamide antithyroid drugs, though this page could not verify an exact quoted source for the wording and presents it as a paraphrased clinical safety point rather than a direct quotation.

Pregnancy and methimazole: a boundary condition, not a detail to skip

Methimazole carries a recognized association with a specific pattern of birth defects (methimazole embryopathy) when used in early pregnancy, which is why PTU is generally preferred during roughly the first trimester and methimazole is often resumed afterward in many clinical practices. This is a decision that should involve the treating endocrinologist or a maternal-fetal medicine specialist, not a cost-based choice, and it is not something this page can individualize for any specific pregnant reader.

When to seek urgent care rather than manage this by cost alone

Fever, sore throat, mouth ulcers, or signs of infection while on methimazole warrant prompt medical evaluation, not a wait-and-see approach based on drug cost. Similarly, symptoms of a thyroid storm (very rapid heart rate, high fever, confusion, severe agitation) are a medical emergency requiring immediate care regardless of insurance or cost status.

Verification checklist: stable facts vs. facts you must confirm this month

Use this to separate what you can rely on from what needs a fresh check before you rely on a number.

Stable, federally or clinically established (unlikely to change month to month):

• Methimazole is FDA-approved for hyperthyroidism, including Graves disease, and generic methimazole is widely available.
• PTU carries an FDA boxed warning for severe liver injury and is generally reserved for first-trimester pregnancy or thyroid storm (FDA).
• Compounding under Section 503A and 503B is a stable federal legal framework, not a state-specific rule.
• Medicare Part D's $2,000 annual out-of-pocket cap has applied nationwide since 2025 (CMS).
• Agranulocytosis and rare hepatotoxicity are recognized, uncommon but serious risks of methimazole that require specific monitoring and symptom awareness.

Date-sensitive, must be confirmed close to the date you act (can change without notice):

• South Dakota Medicaid's current coverage or prior-authorization status for methimazole. Confirm directly with South Dakota Medicaid or the dispensing pharmacy.
• Any specific commercial insurer's formulary tier or copay for methimazole in South Dakota. Confirm with the plan's current formulary document or member services.
• Cash price at a specific South Dakota pharmacy, with or without a discount coupon. Confirm the same day by calling the pharmacy or checking a real-time pricing tool.
• Whether a specific 503A or 503B compounding pharmacy in South Dakota is currently licensed and stocking methimazole preparations. Confirm with the pharmacy and, if needed, the South Dakota Board of Pharmacy.
• Manufacturer savings card terms and eligibility, which change periodically and generally exclude government insurance.
• Telehealth reimbursement rules for your specific insurance plan, separate from the general legality of telehealth prescribing.

If a number you find online for any of the date-sensitive items is not labeled with a date, treat it as unverified.

Frequently asked questions

References

2. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/
3. Centers for Medicare & Medicaid Services. Inflation Reduction Act and Medicare. https://www.cms.gov/inflation-reduction-act-and-medicare

A note on sources removed from the prior version: Several PubMed-linked citations and a quoted sentence attributed to American Thyroid Association guidelines appeared in the earlier draft of this page. They have been removed because they could not be independently verified as accurately linked to the claims they supported. Clinical statements about first-line drug choice, remission rates, and monitoring intervals in this rewrite are described in general terms and flagged for confirmation against the current published guidelines from the American Thyroid Association and the American Association of Clinical Endocrinologists during medical review, rather than presented with a specific citation that could not be checked.